Merit Medical Systems has completed the acquisition of View Point Medical through a merger, bringing the US-based firm fully under its ownership. The Merit Medical acquisition strengthens the company’s position in therapeutic oncology by adding specialised imaging and tissue marker technologies to its portfolio.
The transaction carries a total value of approximately $140m, including assumed liabilities. Merit paid $90m in cash at closing, while the remaining $50m will be disbursed in two deferred payments of $25m each, scheduled no later than the first and second anniversaries of the closing date. With the integration of View Point’s capabilities, Merit is broadening its offering in oncology procedures that require precise tumour localisation and imaging support.
View Point Medical is known for manufacturing the OneMark detection imaging system along with OneMark tissue markers. Cleared by the US Food and Drug Administration, the OneMark platform combines a surgical detection console with ultrasound-enhanced tissue markers. These markers are designed to remain visible across standard imaging modalities after placement, while also minimising interference during imaging procedures. When used alongside Merit’s SCOUT platform, the system may reduce the need for additional pre-surgical procedures to identify tumour locations.
From 1 April 2026 through 31 December 2026, Merit expects the acquisition to generate between $2m and $4m in revenue, while reducing previously forecast non-GAAP earnings per share by $0.05. Over the 12 months ending 31 December 2027, revenue contribution is projected to reach between $14m and $16m, with the deal anticipated to become accretive to non-GAAP earnings per share.
Merit Medical Systems president and CEO Martha Aronson said: “This acquisition expands Merit’s portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localisation of breast and soft tissue tumours.
“View Point’s unique ultrasound-enhanced technology offers a highly innovative solution to localise more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the US alone.”
Financial advisory services for the deal were provided by Piper Sandler, while legal counsel was handled by Baker & McKenzie.
